cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1490Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMС-реактивный белок: современное состояние проблемыC-reactive protein: modern state of the problemЖуковаВ. А.ZhukovaV. A.

аспирант отдела эпидемиологии неинфекционных заболеваний

Москва

VZhukova@gnicpm.ruШальноваС. А.ShalnovaS. A.

руководитель отдела планирования и координации научных исследований

Москва

МетельскаяВ. А.MetelskayaV. A.

руководитель отдела изучения биохимических маркеров риска хронических неинфекционных заболеваний, Ученый секретарь

Москва

Государственный научно-исследовательский центр профилактической медициныРоссияState Research Centre for Preventive MedicineRussian FederationРоссийский кардиологический научно-производственный комплексРоссияRussian Cardiology Scientific and Clinical ComplexRussian Federation2011200220111019095Copyright © Жукова В.А., Шальнова С.А., Метельская В.А., 20112011Жукова В.А., Шальнова С.А., Метельская В.А.Zhukova V.A., Shalnova S.A., Metelskaya V.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1490

В обзоре изложены современные представления о С-реактивном белке (СРБ) как потенциальном факторе риска (ФР) прогрессирования атеросклероза. В настоящее время утверждение о том, что СРБ можно поставить в один ряд с такими классическими ФР, как артериальная гипертония, дислипидемия и курение, не является бесспорным. Однако признается его особая роль в качестве доказанного маркера воспаления, который рекомендуется использовать в клинической практике для уточнения степени риска пациента.

The paper presents the modern views on C-reactive protein (CRP) as a potential risk factor (RF) of atherosclerosis progression. At present, the statement that CRP could be regarded as important as classical RFs (arterial hypertension, dyslipidemia, or smoking) remains controversial. However, CRP is a well-known major inflammatory marker, which is recommended for more accurate risk stratification in clinical practice.

С-реактивный белокатеросклерозвоспалениефакторы рискапрогностическая модельметаболический синдромC-reactive proteinatherosclerosisinflammationrisk factorsprognostic modelmetabolic syndromeReferencesThe World Health Report. Making a Difference. Geneva: World Health Organization 1999.The World Health Report. Making a Difference. Geneva: World Health Organization 1999.The World Health Report 2002: Reducing risks Promoting healthy life. Geneva: World Health Organization 2002.The World Health Report 2002: Reducing risks Promoting healthy life. Geneva: World Health Organization 2002.American Heart Association. Statistical Fact Sheet – Population. International Disease Statistics. Dallas; Tex: American Heart Association 2003.American Heart Association. Statistical Fact Sheet – Population. International Disease Statistics. Dallas; Tex: American Heart Association 2003.Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-47.Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-47.Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated levels of lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84.Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated levels of lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486-97.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486-97.De Backer G, Ambrosisni E, Borch-Johnsen et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24(17): 1601-10.De Backer G, Ambrosisni E, Borch-Johnsen et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24(17): 1601-10.Ridker PM, Paynter NP, Rifai N, C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction. Circulation 2008; 118: 2243-51.Ridker PM, Paynter NP, Rifai N, C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction. Circulation 2008; 118: 2243-51.Khot UN, Khot MB, Baizer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904.Khot UN, Khot MB, Baizer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904.Tillett WS, Francis T. Serologic reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930; 52: 561-71.Tillett WS, Francis T. Serologic reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930; 52: 561-71.McCarty M. The occurrence during acute infections of a protein not normally present in the blood. IV. Crystallization of the C-reactive protein. J Exp Med 1947; 85: 491-8.McCarty M. The occurrence during acute infections of a protein not normally present in the blood. IV. Crystallization of the C-reactive protein. J Exp Med 1947; 85: 491-8.Kroop I, Shackman N. Levels of C-reactive protein as a measure of acute myocardial infarction. Proc Soc Exp Biol Med 1954; 86: 95-7.Kroop I, Shackman N. Levels of C-reactive protein as a measure of acute myocardial infarction. Proc Soc Exp Biol Med 1954; 86: 95-7.Pearson TA, Mensah GA. Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.Pearson TA, Mensah GA. Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.Zacho J, Tybjaerg-Hansen A, Nordestgaard B G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897-908.Zacho J, Tybjaerg-Hansen A, Nordestgaard B G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897-908.Ross R. Atherosclerosis an Inflammatory disease. N Engl J Med 1999; 340(2): 115-26.Ross R. Atherosclerosis an Inflammatory disease. N Engl J Med 1999; 340(2): 115-26.Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-51.Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-51.Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested casecontrol study. Am J Epidemiol 1996; 144: 537-47.Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested casecontrol study. Am J Epidemiol 1996; 144: 537-47.Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9. [Erratum, N Engl J Med 1997;337:356.]Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9. [Erratum, N Engl J Med 1997;337:356.]Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006; 187: 415-22.Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006; 187: 415-22.Ridker PM, High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care. Clinical Chemistry 2008; 54(2): 234-7.Ridker PM, High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care. Clinical Chemistry 2008; 54(2): 234-7.Feskens EJM, Kromhout D. Fibrinogen and factor VII activity as risk factors for cardiovascular disease in an elderly cohort. Can J Cardiol 1997; 13(Suppl B): 282B.Feskens EJM, Kromhout D. Fibrinogen and factor VII activity as risk factors for cardiovascular disease in an elderly cohort. Can J Cardiol 1997; 13(Suppl B): 282B.Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ 2000; 321: 199-204.Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ 2000; 321: 199-204.Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and woman: the Framingham Heart Study. Arterioscl Tromb Vasc Biol 2002; 22: 1662-7.Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and woman: the Framingham Heart Study. Arterioscl Tromb Vasc Biol 2002; 22: 1662-7.Ridker PM, Charles H, Hennekens MD, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.Ridker PM, Charles H, Hennekens MD, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.Koenig W, Sund M, Froelich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle aged men: results from MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.Koenig W, Sund M, Froelich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle aged men: results from MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.Albert MA, Glynn RJ Ridker PM, et al. Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161-5.Albert MA, Glynn RJ Ridker PM, et al. Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161-5.Ridker PM. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J 1998; 19: 1-3.Ridker PM. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J 1998; 19: 1-3.Ford ES. Body Mass Index, Diabetes, and C-Reactive Protein Among U.S. Adults. Diabetes Care 1999; 22: 1971-7.Ford ES. Body Mass Index, Diabetes, and C-Reactive Protein Among U.S. Adults. Diabetes Care 1999; 22: 1971-7.Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.Han TS, Sattar N, Williams K, et al. Prospective Study of C-Reactive Protein in Relation to the Development of Diabetes and Metabolic Syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21.Han TS, Sattar N, Williams K, et al. Prospective Study of C-Reactive Protein in Relation to the Development of Diabetes and Metabolic Syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21.Laaksonen DE, Niskanen L, Nyyssonen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-10.Laaksonen DE, Niskanen L, Nyyssonen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-10.Sesso HD, Burning GE, Rafai N, et al. C-reactive protein and the risk of development hypertension. JAMA 2003; 290: 2945-51.Sesso HD, Burning GE, Rafai N, et al. C-reactive protein and the risk of development hypertension. JAMA 2003; 290: 2945-51.Ridker PM, Cook NR, Lee IM, et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. N Engl J Med 2005; 352.Ridker PM, Cook NR, Lee IM, et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. N Engl J Med 2005; 352.Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.Morrow DA, Lemos JA. Benchmarks for the Assessment of Novel Cardiovascular Biomarkers. Circulation 2007; 115: 949-52.Morrow DA, Lemos JA. Benchmarks for the Assessment of Novel Cardiovascular Biomarkers. Circulation 2007; 115: 949-52.Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-53.Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-53.Cook NR, Buring JE, Ridker PM, et al. The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women. Ann Intern Med 2006; 145: 21-2.Cook NR, Buring JE, Ridker PM, et al. The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women. Ann Intern Med 2006; 145: 21-2.Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297: 611-9.Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297: 611-9.Ridker P, Paynter N, Rifai N. C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men. Circulation 2008; 118(22): 2243-51.Ridker P, Paynter N, Rifai N. C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men. Circulation 2008; 118(22): 2243-51.Zethelius B, Berglund L, SundstrΔm J, et al. Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes. N Engl J Med 2008; 358: 2107-16.Zethelius B, Berglund L, SundstrΔm J, et al. Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes. N Engl J Med 2008; 358: 2107-16.Wang TJ, Gona P, Larson MG, et al. Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death. NEJM 2008; 358: 2107-16.Wang TJ, Gona P, Larson MG, et al. Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death. NEJM 2008; 358: 2107-16.

The authors declare that there are no conflicts of interest present.